Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414490 · ClinicalTrials.gov registry record
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
A clinical trial of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by University of Minnesota.
- Completed
- Registry status
- 30
- Enrollment target
- 7
- Study locations
NCT02414490: Completed study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by University of Minnesota.
NCT02414490 is a study of Chronic Inflammatory Demyelinating Polyneuropathy that has completed, run by University of Minnesota. The registered enrollment target is 30 participants, below the 158-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (81% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02414490, a study of Chronic Inflammatory Demyelinating Polyneuropathy, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a prospective observational study of 30 adult CIDP patients who receive home IVIg infusion services from AxelaCare Health Solutions, LLC. The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
Primary Outcome
Extent of treatment related fluctuations to intravenous immunoglobulin (IVIg) in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) using a Jamar Dynamometer to capture daily grip strength (GS) measurements
Conditions Studied
Interventions
- DRUG Intravenous Immunoglobulin
Study Locations (7)
Georgia
- Neurology at John's Creek - Johns Creek
Illinois
- Northwestern University - Chicago
Kansas
- University of Kansas Medical Center - Kansas City
Minnesota
- University of Minnesota - Minneapolis
New Hampshire
- Dartmouth-Hitchcock Medical Center/Dartmouth Geisel School of Medicine - Lebanon
New York
- Columbia University Medical Center - New York
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-03 |
| Est. Completion | 2020-05 |
What the finished NCT02414490 record still lists
NCT02414490 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 158-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Intravenous Immunoglobulin is the first listed.
NCT02414490 lists 7 locations in 7 states (Georgia, Illinois, Kansas).
Frequently Asked Questions
What is clinical trial NCT02414490 about?
NCT02414490 is a clinical study titled "IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements". This is a prospective observational study of 30 adult CIDP patients who receive home IVIg infusion services from AxelaCare Health Solutions, LLC. The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
What is the current status of trial NCT02414490?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2015-03. Estimated completion is 2020-05.
What conditions does trial NCT02414490 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT02414490?
The interventions under investigation include: Intravenous Immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT02414490?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02414490 being conducted?
This trial has 7 study locations across Georgia, Illinois, Kansas, Minnesota, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02414490's enrollment target sits among peer trials
30 9th of 11 higher than 3 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia